Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2025-05-29 Annual Report
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
General Updates
Annual Report Classification · 95% confidence The document is a detailed announcement from Concord Biotech Limited dated May 29, 2025, reporting the outcome of a Board Meeting where the audited financial results for the quarter and financial year ended March 31, 2025, were approved and taken on record. It includes the approval of standalone and consolidated audited financial results, dividend recommendation, appointment of company secretary, appointment of auditors (secretarial, internal, and cost auditors), and includes audit reports with unmodified opinions from statutory auditors. The document also contains annexures with detailed profiles of appointed auditors and company secretary. The presence of comprehensive financial results, audit opinions, and detailed financial year-end data indicates this is the actual Annual Report or the core financial results document rather than a brief announcement or certification. The length (15,000 characters) and detailed content confirm it is not a short announcement or a certification letter. Therefore, the document fits the definition of an Annual Report (10-K) as it covers the full financial performance and company activity for the fiscal year ending March 31, 2025. FY 2025
2025-05-29 English
Change in Company Secretary/Compliance Officer
Annual Report Classification · 95% confidence The document is a detailed announcement from Concord Biotech Limited dated May 29, 2025, reporting the outcome of a Board Meeting where the audited financial results for the quarter and financial year ended March 31, 2025, were approved and taken on record. It includes the approval of standalone and consolidated audited financial results, dividend recommendation, appointment of company secretary, appointment of auditors (secretarial, internal, and cost auditors), and includes audit reports with unmodified opinions from the statutory auditors. The document also contains annexures with detailed profiles of appointed auditors and company secretary. The document is lengthy (15,000 characters) and contains substantive financial data and audit opinions, not merely an announcement or a certification. It is not a short notice or a simple declaration but a comprehensive disclosure of audited financial results and related board decisions. Therefore, it fits the definition of an Annual Report (10-K) type filing, as it covers the full financial performance and related corporate governance decisions for the fiscal year. It is not just an announcement of the report (RPA) or a certification (RNS). FY 2025
2025-05-29 English
Integrated Filing- Financial
Annual Report Classification · 95% confidence The document is a detailed announcement from Concord Biotech Limited dated May 29, 2025, reporting the outcome of a Board Meeting where the audited financial results for the quarter and financial year ended March 31, 2025, were approved and taken on record. It includes references to the audit committee, statutory auditors' unmodified opinion, and detailed financial results. It also contains information about dividend recommendation, appointment of company secretary, appointment of auditors, and annexures with profiles of auditors. The document includes an audit report excerpt from BSR & Co. LLP, confirming the audit of standalone annual financial results for the year ended March 31, 2025. The length of the document (15,000 characters) and the presence of substantive financial data and audit opinions indicate this is not merely an announcement but the actual audited financial results report. The document is comprehensive and contains financial statements and audit opinions, which aligns with the characteristics of an Annual Report (10-K equivalent). Therefore, the filing type is Annual Report (10-K). FY 2025
2025-05-29 English
Dividend
Audit Report / Information Classification · 95% confidence The document is a detailed announcement from Concord Biotech Limited dated May 29, 2025, reporting the outcome of a Board Meeting where the audited financial results for the quarter and financial year ended March 31, 2025, were approved and taken on record. It includes the approval of standalone and consolidated audited financial results, dividend recommendation, appointment of company secretary, appointment of auditors (secretarial, internal, and cost auditors), and includes audit reports with unmodified opinions from statutory auditors. The document also contains annexures with detailed profiles of appointed auditors and company secretary. The presence of comprehensive financial results, audit opinions, and detailed management decisions related to the financial year-end indicates this is a full Annual Report or equivalent filing. However, the document is not the full Annual Report (10-K equivalent) itself but rather the official announcement of the audited financial results and related board decisions. The document is lengthy (15,000 characters) and contains substantive financial and audit information, not just a brief announcement or certification. Given the nature of the content, it fits best under the category of Audit Report / Information (AR), as it includes audit opinions and detailed audit-related information but is not the full Annual Report (10-K). It is more than a simple earnings release or dividend notice, and it is not a regulatory filing or report publication announcement. Therefore, the classification is AR with high confidence. FY 2025
2025-05-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an invitation to an earnings conference call scheduled for May 30, 2025, to discuss the audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2025. It includes details about the call participants, dial-in numbers, and registration links. The document does not contain actual financial results or substantive financial data but is rather an announcement of the earnings call event. According to the classification rules, such documents are classified as Call Transcript (CT) only if they contain the full transcript of the call. Since this is only an invitation and not the transcript, it does not qualify as CT. It is also not an Earnings Release (ER) because it does not contain key financial highlights or results. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the earnings call event, which does not fit other specific categories.
2025-05-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is an invitation to an earnings conference call scheduled for May 30, 2025, to discuss the audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2025. It includes details about the call participants, dial-in numbers, and registration links. The document does not contain actual financial results or detailed financial statements but is an announcement of the earnings call event. Therefore, it is classified as a Call Transcript (CT) invitation rather than the transcript itself or an earnings release. However, since it is an invitation to the earnings call, the best fitting category is Call Transcript (CT) as it relates to the earnings call event.
2025-05-26 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.